Diasome Pharmaceuticals is at the forefront of developing innovative therapies targeting metabolic disorders, particularly focusing on diabetes management. Their proprietary Hepatocyte Directed Vesicles (HDV™) technology is designed to deliver therapeutic agents such as insulin, serotonin, and GLP-1 directly to hepatocyte cells, which are crucial for regulating glucose and lipid metabolism in the body. By restoring the function of these cells, Diasome aims to address the underlying deficiencies that contribute to conditions like Type 1 and Type 2 diabetes, as well as dyslipidemia. The HDV system can be administered both orally and via injection, allowing for customizable treatment options that enhance the efficacy of the drugs while maintaining a pristine safety profile demonstrated in human trials.

The company's research emphasizes the central role of hepatocytes in maintaining metabolic balance, as these cells are responsible for the storage and release of glucose and the regulation of lipid levels. Disruptions in hepatocyte function can lead to significant metabolic issues, including hyperglycemia and chronic conditions such as non-alcoholic fatty liver disease (NAFLD). Diasome's pipeline includes various formulations of HDV targeting different metabolic pathways, showcasing their commitment to developing safe and effective treatments tailored to meet the needs of patients living with metabolic disorders.

United States

Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell targeting to restore hepatocyte metabolism and treat metabolic diseases. Restoring hepatocyte function addresses the root dysregulations in common metabolic diseases like diabetes, obesity, and dyslipidemia. Our therapies leverage the Hepatocyte's natural regulatory functions, aiming to deliver superior patient outcomes and improved disease management. 

Diasome Pharmaceuticals

Company Details